TWST (Twist Bioscience) Short-Term Debt: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TWST Twist Bioscience Corp TWST
69 GF Score
Price $114.03
GF Value $52.17
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Twist Bioscience Short-Term Debt?

Twist Bioscience TWST +4.54% 69 Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $52.17 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Twist Bioscience's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.0 Mil.

Twist Bioscience Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Twist Bioscience Short-Term Debt Related Terms

Twist Bioscience Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Twist Bioscience's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Twist Bioscience Short-Term Debt Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 0.00 0.00 0.00 0.00

Twist Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TWST
69GF Score
Twist Bioscience Corp TWST
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.0 Mil mean?
Twist Bioscience (TWST) has a Short-Term Debt of $0.0 Mil as of Jun. 2026.
Is Twist Bioscience's Short-Term Debt too high?
Twist Bioscience's current Short-Term Debt is $0.0 Mil. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Short-Term Debt compare to BLLN and SHC?
Twist Bioscience's Short-Term Debt of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Twist Bioscience's current Short-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.17, compared to a current price of $114.03 — trading 118.6% above its estimated fair value. The current Short-Term Debt is $0.0 Mil. Twist Bioscience's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Twist Bioscience (TWST), the current Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Twist Bioscience (TWST) Overvalued in 2026?

Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued. The current stock price of $114.03 is trading 118.6% above its estimated GF Value™ of $52.17. GuruFocus considers Twist Bioscience to be Significantly Overvalued.

Key valuation signals for TWST:

  • Short-Term Debt: $0.0 Mil
  • GF Value™: $52.17 vs. price of $114.03 (118.6% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Twist Bioscience Business Description

Other Exchanges 1TWST:Italy0ME:Germany
Address 681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score

Get the complete analysis for TWST

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$114.03
Price
$52.17
GF Value